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因其病理特征主要分为非小细胞肺癌（non small cell lung cancer, NSCLC）和小








色质的结构。组蛋白赖氨酸的甲基化主要由包含 SET（ Suppressor of variegation, 
Enhancer of Zeste, and Trithorax）结构域的甲基转移酶催化完成，与染色质结构
激活相关的有 H3K4、H3K36、H3K79 甲基化等，而与沉默区域相关的有 H3K9、
H3K27 甲基化等。有报道称 DNA 损伤修复蛋白 53BP1 在 DSB(double strands 
break)位点的招募需要组蛋白 H4 的乙酰化和 H4K20 的甲基化。有研究证实在裂
殖酵母中，依赖 Set2 的 H3K36 甲基化可以促进非同源末端连接，且依赖 Gcn5
的 H3K36 乙酰化可以促进同源重组修复。2010 年有文献报道了在酵母细胞中，
由 Set1p 催化的 H3K4me3 在 DNA 损伤修复中发挥着重要作用，且 Set1p 依赖于




生呢？本课题采用两株遗传背景不同的肺腺癌细胞 A549（K-Ras G12S 突变）和
H1299(P53 缺失)建立了辐射抗性模型。通过分子生物学手段分析发现，不同遗
传背景的肺癌细胞产生辐射抗性的表观遗传学机制不同，并且在 A549 细胞中，
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Lung cancer is one of the diseases leading to the death of human cancer today, 
the incidence of men in the first place and women occupy the second place. 
According to statistics, the number of deaths due to lung cancer each year has more 
than 1 million cases. According to pathological and clinical features，Lung cancer can 
be divided into non-small cell lung cancer (NSCLC) and small cell lung cancer 
(SCLC) two categories. NSCLC accounted for 80 to 90%. Most patients with NSCLC 
often lose their chances of surgery, mainly using radiotherapy-based combined 
therapy or radiotherapy alone, but the survival rate is only about 5%. The effect of 
radiation therapy on cancer cells is the sensitivity of cancer cells to ionizing radiation, 
but tumor cells are often resistant to ionizing radiation because of the mechanism of 
DNA damage repair, and thus limit the application of radiotherapy. 
The main indicator of epigenetic network is the covalent modification of 
chromatin, which can directly regulate the expression of genes and determine the 
important role of cell proliferation and differentiation , and it can work as a bridge 
between the internal and external environmental factors and genome genetic 
information. Histone methylation, acetylation and ubiquitination and other 
modifications can alter the transcriptional properties of DNA and the structure of 
chromatin. Methylation of histone lysine is catalyzed primarily by methyltransferase 
comprising the SET (Suppressor of Variegation, Enhancer of Zeste, and Trithorax) 
domain. Usually H3K4, H3K36, H3K79 methyl groups associated with chromatin 
structural activation and H3K9, H3K27 methyl groups associated with the silence 
region. It has been reported that the recruitment of DNA damage repair protein 53BP1 
at the DSB site requires the acetylation of histone H4 and the methylation of H4K20. 
There are studies have shown that H2K36 methylation, which is dependent on Set2, 
can promote non-homologous terminal attachment (NHEJ) in fission yeast, and that 
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repair (HR). In 2010, it has been reported tht H3K4me3 catalyzed by Set1p plays an 
important role in DNA DSB repair in yeast cells, and Set1p is dependent on RSC 
complexes. H3K4me3, a positive histone modification regulated by menin and MLL, 
which, in addition to regulating the activity of some gene promoters to promote gene 
transcription, can also alter the conformation of chromatin and make it more loose. So 
does this histone modification mechanism and its methyltransferase TrxG complex 
also participate in the radiation damage induced by ionizing radiation in lung cancer 
cells, and then participate in the radiation resistance of lung cancer cells. In this study, 
two radiation resistant models were established using two lung adenocarcinoma cells 
A549 (K-Ras G12S mutant) and H1299 (P53 null). By means of molecular biology 
analysis, it was found that the epigenetic mechanisms of radiation resistance of lung 
cancer cells with different genetic backgrounds were different, and in A549 cells, the 
methyl transferase of H3K4me3 and the MLL of TrxG complex were produced in 
radiation resistance And then decreased to demonstrate that MLL was involved in the 
production of radiation resistance and that H3K4me3 was activated at the 
transcription initiation site. 
Thus, this study provides a new idea for the epigenetic mechanisms of radiation 
resistance of lung cancer cells. This will provide a new molecular marker for the 
rational development of lung cancer radiotherapy program, and provide interesting 
ideas for the study of radiotherapy sensitizer in lung cancer. 
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  第一章 前 言 
1.1 肺癌简介 
肺癌是目前世界范围内发病率和死亡率最高的恶性肿瘤之一。据统计，2012
年，全球有 1.8 百万人被确诊为肺癌，且 1.6 百万人死于肺癌，占所有癌症患者







































类型：小细胞肺癌（small cell lung cancer SCLC）占 13%，以及非小细胞肺癌（Non 
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（Adenocarcinoma ADC）、鳞细胞癌（Squamous cell carcinoma SqCC）以及大细
胞肺癌（Large cell lung cancer LCLC）[14, 12, 15]。下位于肺上皮部位[16]。它被认为
是一种恶性上皮性肿瘤，并伴有腺体的分化，该分化可以通过粘蛋白卡红染色以
及肺细胞标志物天冬氨酸蛋白酶 A 或者甲状腺转录因子 1 等来识别[17, 18]。一般
情况下，肺腺癌主要集中在肺部的周围[16, 18, 19]。 并且，肺腺癌有多种不同的组
织类型，经常与相似的肿瘤包括在鳞状细胞，腺泡，乳突状，微乳突状以及实体
瘤等混杂在一起，通常，鳞细胞癌预后良好，而微乳突状与实体瘤预后较差[11, 17]。  
实质肺腺癌通常也会与鳞细胞癌或者大细胞癌所混淆，因此，免疫组化检测天冬
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EGFR 基因位于 7 号染色体短臂 12 区[23]。该基因编码一种跨膜糖蛋白，属
于蛋白激酶超家族的成员[24]。调查表明，非小细胞肺癌以及其他上皮癌症患者
中， 有 40%-80%患者存在 EGFR 过表达。且在美国有 10%，东亚 35%的肺癌患
者中存在EGFR的突变[25-27]。这些突变多发生于编码EGFR蛋白激酶区域的18-21
位外显子上。EGFR 突变通常是杂合性的，通常突变的基因使得该基因拷贝增加
[28]。将近 90%这种突变发生在外显子 19 上，将 CTG 转变成 CCG，或者是外显




EGFR 突变的肿瘤患者对于 EGFR 酪氨酸激酶抑制剂（EGFR TKIs）很敏感，例
如吉非替尼，埃罗替尼和拉法替尼等。但许多患者用药后会再次复发产生耐药，




参与调控细胞分裂[31]。K-RAS 是 ras/MAPK 信号通路里面的一个成员，它负责
将细胞外的信号传递到细胞核内[32]。K-RAS 突变在胰腺癌中占 60%-90%，结肠
癌中有 35%，浆液性卵巢癌中有 20%，甲状腺癌中有 15%。在肺腺癌中，K-RAS
的激活点突变经检测大致有 15%-25%左右。但在肺鳞癌里面不常见[33]。K-RAS
的突变对于促进致癌过程的发生至关重要[34] 。在癌细胞中，K-RAS 的突变较高




















的突变预示着会耐受靶向治疗药物 EGFR TKIs[39, 40]。据分子检测分析：含有在
内含子 1，密码子 12、13 和 61 的 K-RAS 激活突变，无论是否有 EGFR 拷贝数的
增加，如果患者采用 EGFR TKIs 药物治疗，将会有 96%的几率使得患者病情加
重，即促进肿瘤的生长[41]。所以含有 K-RAS 突变的患者预示着其不适宜用 EGFR 
TKIs 药物埃罗替尼以及吉非替尼进行治疗[39, 42]。K-RAS 信号通路，即：K-RAS
与跨膜生长因子受体相结合将保外信号传递至胞内。K-RAS 蛋白以法尼基化形
式结合在细胞膜上，在激活和未激活状态之间来回转换进而调控下游的信号通路。
未激活时，K-RAS 与 GDP 相结合，鸟苷酸交换因子催化 GDP 转变成 GTP，然
后激活 K-RAS[43]。激活的 K-RAS 促进下游生长因子信号通路参与细胞增殖、生
存以及转移等。GTP 酶激活蛋白水解 GTP 为 GDP 致使信号终止。K-RAS 突变通
常与其它促肺癌分子 EGFR 突变以及 ALK 融合蛋白在促进癌症发生过程中相互
独立。且发现它与许多异常肿瘤抑制基因相共存。从癌症体细胞突变目录的数据
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